XpresSpa Group, Inc. (NASDAQ:XSPA) has rebounded strongly over the last week, with the share price soaring 49%. But...

Under the terms of the securities purchase agreement, XpresSpa has agreed to sell approximately 8,750,000 common shares (or pre-funded warrants to purchase common shares in lieu thereof). The gross proceeds to the Company from the registered direct offering is expected to be approximately $1.79 million before deducting fees and other estimated offering expenses.

XpresSpa will also bring massage therapists and chairs (mini spa) to the event for the benefit of participants. Separately, XpresSpa also announced that it will report its fourth quarter 2019 financial results after the close of the financial markets on Monday, March 30th. The webcast can be accessed from Investor Relations section of the Company’s website at http://xpresspagroup.com.

The Company has engaged in early high-level discussions with regards to turning all of its 46 airport locations, with many, located in point of entry cities, such as New York, Los Angeles, San Francisco, Chicago, Miami, Atlanta, and Washington DC into COVID-19 testing facilities. The Company believes that its spas offer a range of spaces that can be set up to test airport staff, flight crews, and passengers. XpresSpa, having locations in all of these key ports of entry is uniquely positioned to help in this fight.

Doctor Lipsey’s role, which is a new position at XpresSpa, will include working alongside healthcare officials to help design safe and compliant protocols, as well as train employees on COVID-19 testing. Since March 19, 2020, XpresSpa has been in advanced discussions with healthcare partners to develop a model for COVID-19 screening and testing in U.S. airports and has created the XpresTest, a wholly-owned subsidiary of XpresSpa Group, Inc, to administer such screening and testing capabilities.

Michael Lebowitz is the Founder and CEO of globally-recognized agency Big Spaceship. Since launching Big Spaceship in 2000, he has defined its strategy and vision, while working closely with the agency’s clients, including Brightstar Care, JPMorgan Chase, Google Fi, Google Maps, Hasbro, International Rescue Committee, JetBlue, Kirkus, the NFL, Roku, SiriusXM, Stadia, Starbucks, and YouTube.

The Company is pleased to announce that it has signed a contract with JFK International Air Terminal LLC (“JFKIAT”) to pilot test its concept of providing diagnostic COVID-19 tests located in Terminal 4. To facilitate the JFK pilot test, the Company has signed an agreement with JFKIAT for a new modular constructed testing facility within the terminal.

Now available on the Apple App Store (iOS) and Google Play (Android), guests who download the XpresSpa app during the first four weeks of the launch will receive a $10 gift certificate towards their next service for the first four weeks of the launch. XpresSpa Group, Inc. (XSPA) is a health and wellness holding company.

A six-year concession dispute at the Atlanta airport, which was reportedly settled in December, apparently won't be fully resolved until 2020.

The company would turn all 46 airport locations, with many, located in point of entry cities, such as New York, Los Angeles, San Francisco, Chicago, Miami, Atlanta, and Washington D.C. into COVID-19 testing facilities.

Under the terms of the securities purchase agreement, XpresSpa has agreed to sell approximately 13,863,636 common shares (or pre-funded warrants to purchase common shares in lieu thereof). The gross proceeds to the Company from the registered direct offering is expected to be approximately $3.05 million before deducting fees and other estimated offering expenses.

Under the terms of the securities purchase agreement, XpresSpa has agreed to sell approximately 10,000,000 common shares (or pre-funded warrants to purchase common shares in lieu thereof). The gross proceeds to the Company from the registered direct offering is expected to be approximately $2.0 million before deducting fees and other estimated offering expenses.

XpresSpa will present at the 22nd Annual ICR Conference today, Tuesday, January 14, 2020 at the Grande Lakes Hotel and Resort in Orlando, Florida. The webcast and accompanying presentation can be accessed from Investor Relations section of the Company’s website at http://xpresspagroup.com.

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / XpresSpa Group, Inc. (NASDAQ:XSPA) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at 4:30 ...

Sanctifly is a fast growing subscription-based app which provides its frequent flying members with access to a global network of health and wellness facilities in and around airports. Under the terms of the agreement, XpresSpa will be one of the largest corporate partners at which Sanctify subscribers can use $30 vouchers towards spa services at any domestic XpresSpa location.

COVID-19 screening and testing would be conducted by converting select existing spa locations for this purpose on an interim basis and over time, potentially adding separate, standalone airport locations as testing sites. XpresSpa’s U.S. airport real estate portfolio consists of 46 locations across 23 airports that are ready to be reactivated and redeployed in short order, subject to the approval of local airport authorities.

The Company has made plans for a smooth transition. Mr. Weinstein is a finance and accounting senior executive with over 30 years of “hands-on” public and private company management, investment banking and private equity investing experience.

XpresSpa will be partnering (the “Partnership”) with Relevant Healthcare Cost Containment®, the registered trade name of Contain Holdings, LLC, an Illinois limited liability company (“Relevant Healthcare”), a Chicago-area healthcare cost containment, payment integrity and transparency company. Relevant Healthcare had previously announced that it is offering testing for COVID-19 (the “COVID-19 testing”) through its contracts with both Laboratory Corporation of America® (“LabCorp”) and Quest Diagnostics™ (“Quest”). All COVID-19 testing will be done by appropriately licensed health professionals in accordance with applicable federal and state laws.

Under the terms of the securities purchase agreement, XpresSpa has agreed to sell approximately 6,285,716 common shares (or pre-funded warrants to purchase common shares in lieu thereof). Separately, XpresSpa also has entered into an exchange agreement with certain of its warrant holders to exchange their existing warrants into shares of the Company’s common stock on a 1.5:1 basis effective upon receipt of shareholder approval.

Shares of XpresSpa Group Inc. were vaulted 84% higher toward a 3-month high on record volume Friday, after the airport retailer of spa equipment announced a contract with New York's JFK International Air Terminal LLC (JFKIAT) to provide diagnostic COVID-19 testing locations. Trading volume spiked to 178 million shares, already a one-day record for the stock which went public in July 2010, and enough to make the stock the most actively traded on major U.S. exchanges. The company said before the open that the deal with JFKIAT is for a new modular constructed testing facility within JFK's Terminal 4, which will host new separate testing rooms with a capacity of 500 tests per day. The testing service will be reserved for airline employees, contractors and workers, concessionaires, TSA officers and U.S. Customs and Border Protection agents. The company said it was working with the Port Authority of New York and New Jersey on other testing locations. The stock has now gained 41% year to date, while the S&P 500 has lost 9.1%.